Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

Robert D. Mass, Michael F. Press, Steven Anderson, Melody A. Cobleigh, Charles Vogel, Noel Dybdal, Grazyna Leiberman, Dennis J. Slamon, Virginia E. Paton

Research output: Contribution to journalArticle

266 Citations (Scopus)

Abstract

Background: We evaluated the influence of HER2 gene amplification, as determined by fluorescence in situ hybridization (FISH), on clinical outcomes (objective response rates, time to disease progression, and overall survival time) in women with metastatic breast cancer treated with trastuzumab in 3 clinical trials. Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay. Materials and Methods: Specimens with a HER2:CEP17 ratio of ≥ 2:0 were considered positive for gene amplification. All specimens had previously demonstrated overexpression of HER2 protein at the 2+ or 3+ level by immunohistochemistry using the Clinical Trials Assay. Response rate, time to disease progression, and survival times were then compared between the FISH-positive and FISH-negative cohorts in each of the 3 clinical trials. Results: Informative FISH results were obtained in 765 (96%) of the 799 patients enrolled in the 3 clinical trials. Overall, 596 (78%) were FISH-positive and 169 (22%) were FISH-negative. The proportion of FISH-positive patients was comparable in all 3 trials. Clinical benefit from trastuzumab therapy appeared to be restricted to patients with FISH-positive metastatic breast cancer. In each clinical trial, the cohort of FISH-positive patients had higher overall response rates and longer durations of survival compared with FISH-negative patients. Conclusion: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy.

Original languageEnglish
Pages (from-to)240-246
Number of pages7
JournalClinical Breast Cancer
Volume6
Issue number3
DOIs
StatePublished - Jan 1 2005

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
Clinical Trials
Gene Amplification
Survival
Disease Progression
Trastuzumab
erbB-2 Genes
Immunohistochemistry

Keywords

  • Chemotherapy
  • Clinical benefit
  • Combined therapy
  • Response
  • Survival
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. / Mass, Robert D.; Press, Michael F.; Anderson, Steven; Cobleigh, Melody A.; Vogel, Charles; Dybdal, Noel; Leiberman, Grazyna; Slamon, Dennis J.; Paton, Virginia E.

In: Clinical Breast Cancer, Vol. 6, No. 3, 01.01.2005, p. 240-246.

Research output: Contribution to journalArticle

Mass, Robert D. ; Press, Michael F. ; Anderson, Steven ; Cobleigh, Melody A. ; Vogel, Charles ; Dybdal, Noel ; Leiberman, Grazyna ; Slamon, Dennis J. ; Paton, Virginia E. / Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. In: Clinical Breast Cancer. 2005 ; Vol. 6, No. 3. pp. 240-246.
@article{9a543be33ede4125ad57583757dc3b59,
title = "Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab",
abstract = "Background: We evaluated the influence of HER2 gene amplification, as determined by fluorescence in situ hybridization (FISH), on clinical outcomes (objective response rates, time to disease progression, and overall survival time) in women with metastatic breast cancer treated with trastuzumab in 3 clinical trials. Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay. Materials and Methods: Specimens with a HER2:CEP17 ratio of ≥ 2:0 were considered positive for gene amplification. All specimens had previously demonstrated overexpression of HER2 protein at the 2+ or 3+ level by immunohistochemistry using the Clinical Trials Assay. Response rate, time to disease progression, and survival times were then compared between the FISH-positive and FISH-negative cohorts in each of the 3 clinical trials. Results: Informative FISH results were obtained in 765 (96{\%}) of the 799 patients enrolled in the 3 clinical trials. Overall, 596 (78{\%}) were FISH-positive and 169 (22{\%}) were FISH-negative. The proportion of FISH-positive patients was comparable in all 3 trials. Clinical benefit from trastuzumab therapy appeared to be restricted to patients with FISH-positive metastatic breast cancer. In each clinical trial, the cohort of FISH-positive patients had higher overall response rates and longer durations of survival compared with FISH-negative patients. Conclusion: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy.",
keywords = "Chemotherapy, Clinical benefit, Combined therapy, Response, Survival, Targeted therapy",
author = "Mass, {Robert D.} and Press, {Michael F.} and Steven Anderson and Cobleigh, {Melody A.} and Charles Vogel and Noel Dybdal and Grazyna Leiberman and Slamon, {Dennis J.} and Paton, {Virginia E.}",
year = "2005",
month = "1",
day = "1",
doi = "10.3816/CBC.2005.n.026",
language = "English",
volume = "6",
pages = "240--246",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab

AU - Mass, Robert D.

AU - Press, Michael F.

AU - Anderson, Steven

AU - Cobleigh, Melody A.

AU - Vogel, Charles

AU - Dybdal, Noel

AU - Leiberman, Grazyna

AU - Slamon, Dennis J.

AU - Paton, Virginia E.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Background: We evaluated the influence of HER2 gene amplification, as determined by fluorescence in situ hybridization (FISH), on clinical outcomes (objective response rates, time to disease progression, and overall survival time) in women with metastatic breast cancer treated with trastuzumab in 3 clinical trials. Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay. Materials and Methods: Specimens with a HER2:CEP17 ratio of ≥ 2:0 were considered positive for gene amplification. All specimens had previously demonstrated overexpression of HER2 protein at the 2+ or 3+ level by immunohistochemistry using the Clinical Trials Assay. Response rate, time to disease progression, and survival times were then compared between the FISH-positive and FISH-negative cohorts in each of the 3 clinical trials. Results: Informative FISH results were obtained in 765 (96%) of the 799 patients enrolled in the 3 clinical trials. Overall, 596 (78%) were FISH-positive and 169 (22%) were FISH-negative. The proportion of FISH-positive patients was comparable in all 3 trials. Clinical benefit from trastuzumab therapy appeared to be restricted to patients with FISH-positive metastatic breast cancer. In each clinical trial, the cohort of FISH-positive patients had higher overall response rates and longer durations of survival compared with FISH-negative patients. Conclusion: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy.

AB - Background: We evaluated the influence of HER2 gene amplification, as determined by fluorescence in situ hybridization (FISH), on clinical outcomes (objective response rates, time to disease progression, and overall survival time) in women with metastatic breast cancer treated with trastuzumab in 3 clinical trials. Breast cancer tissue specimens were evaluated using a direct labeled, dual-probe FISH assay. Materials and Methods: Specimens with a HER2:CEP17 ratio of ≥ 2:0 were considered positive for gene amplification. All specimens had previously demonstrated overexpression of HER2 protein at the 2+ or 3+ level by immunohistochemistry using the Clinical Trials Assay. Response rate, time to disease progression, and survival times were then compared between the FISH-positive and FISH-negative cohorts in each of the 3 clinical trials. Results: Informative FISH results were obtained in 765 (96%) of the 799 patients enrolled in the 3 clinical trials. Overall, 596 (78%) were FISH-positive and 169 (22%) were FISH-negative. The proportion of FISH-positive patients was comparable in all 3 trials. Clinical benefit from trastuzumab therapy appeared to be restricted to patients with FISH-positive metastatic breast cancer. In each clinical trial, the cohort of FISH-positive patients had higher overall response rates and longer durations of survival compared with FISH-negative patients. Conclusion: These data indicate that assessment of HER2 amplification by FISH is the preferred method to select patients for trastuzumab therapy.

KW - Chemotherapy

KW - Clinical benefit

KW - Combined therapy

KW - Response

KW - Survival

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=25144517586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144517586&partnerID=8YFLogxK

U2 - 10.3816/CBC.2005.n.026

DO - 10.3816/CBC.2005.n.026

M3 - Article

C2 - 16137435

AN - SCOPUS:25144517586

VL - 6

SP - 240

EP - 246

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 3

ER -